First Trust Advisors LP boosted its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 55.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 338,876 shares of the company's stock after purchasing an additional 121,483 shares during the period. First Trust Advisors LP's holdings in Eli Lilly and Company were worth $392,107,000 at the end of the most recent reporting period.
Several other large investors also recently added to or reduced their stakes in LLY. BlackRock Inc. raised its position in Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock valued at $81,009,981,000 after acquiring an additional 1,046,558 shares in the last quarter. State Street Corp grew its position in Eli Lilly and Company by 1.7% in the second quarter. State Street Corp now owns 36,215,754 shares of the company's stock worth $43,438,262,000 after acquiring an additional 605,752 shares in the last quarter. Bank of America Corp DE bought a new stake in Eli Lilly and Company in the second quarter worth approximately $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Eli Lilly and Company by 1.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company's stock worth $8,647,153,000 after purchasing an additional 137,364 shares during the last quarter. Finally, Jennison Associates LLC increased its stake in shares of Eli Lilly and Company by 7.9% during the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company's stock worth $6,550,587,000 after purchasing an additional 400,538 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.
Key Headlines Impacting Eli Lilly and Company
Here are a few of the latest headlines about LLY:
- Positive Sentiment: Health Canada approved Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes, potentially broadening the drug’s use and commercial opportunity. Article: Health Canada approves Lilly’s Mounjaro
- Positive Sentiment: Lilly is expanding its oncology research through the acquisition of Calytrix Bio and a multi-target collaboration with Stipple Bio. The deals add programs and research capabilities, though their financial impact will depend on development progress. Article: Eli Lilly expands its oncology research platform
- Negative Sentiment: Some coverage warns that Lilly’s roughly $1.4 trillion valuation leaves substantial expectations embedded in the shares. That could make the stock more sensitive to any slowdown in growth or disappointing clinical results. Article: Eli Lilly’s valuation is heavy with hope
Analysts Set New Price Targets
LLY has been the topic of a number of recent research reports. Sanford C. Bernstein reaffirmed an "outperform" rating and issued a $1,450.00 price objective on shares of Eli Lilly and Company in a research note on Monday, October 26th. Barclays upped their price objective on shares of Eli Lilly and Company from $1,400.00 to $1,550.00 and gave the stock an "overweight" rating in a report on Monday, November 16th. Guggenheim increased their target price on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a "buy" rating in a research report on Friday, September 18th. Argus raised their target price on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a "buy" rating in a report on Friday, October 30th. Finally, Berenberg Bank raised Eli Lilly and Company from a "hold" rating to a "buy" rating and set a $1,400.00 price target for the company in a research report on Tuesday, September 15th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,422.00.
Read Our Latest Stock Analysis on Eli Lilly and Company
Eli Lilly and Company Price Performance
Shares of NYSE:LLY opened at $1,346.40 on Friday. The company has a market cap of $1.27 trillion, a price-to-earnings ratio of 43.70, a PEG ratio of 1.61 and a beta of 0.40. The business has a 50 day moving average price of $1,268.06 and a 200 day moving average price of $1,119.25. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,475.25.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. During the same period in the previous year, the business posted $7.02 EPS. The company's revenue for the quarter was up 38.6% on a year-over-year basis. Research analysts predict that Eli Lilly and Company will post 35.73 earnings per share for the current year.
Eli Lilly and Company Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 22.46%.
Insider Transactions at Eli Lilly and Company
In related news, EVP Anat Hakim sold 5,000 shares of the company's stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the transaction, the executive vice president directly owned 4,137 shares in the company, valued at $5,802,225.24. This represents a 54.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.14% of the company's stock.
About Eli Lilly and Company
(
Free Report)
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company's medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.